Five Below Inc vs Merck & Co., Inc. — how do they compare? Five Below Inc trades at $213.18 (market cap $11.55B), while Merck & Co., Inc. trades at $145.72 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 30.4× Five Below Inc's market cap, and Merck & Co., Inc. pays a 2.39% dividend while Five Below Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Five Below Inc for 46 Days and Merck & Co., Inc. for 98 Days on average.
| FIVE | MRK | |
|---|---|---|
Market Cap | $11.55B | $351.28B |
Volume | 1,120,554 | 7,969,665 |
Sector | Consumer Cyclical | Health |
52-Week High | $262.72 | $156.43 |
52-Week Low | $138.49 | $82.49 |
Typical Hold Time | 46 Days | 98 Days |
Enterprise Value | $12.40B | $398.04B |
Dividend Yield | — | 2.39% |
Signals from Pluang's Aura AI — not financial advice
Five Below (FIVE) trades at $204.24, down 2.71% today, with strong analyst support (60% buy ratings) and a consensus price target of $298.44. The stock shows robust fundamentals with revenue growth from $3.6B in 2024 to $3.9B in 2025 and projected $5.3B in 2026, alongside consistent earnings beats. Technical indicators are mixed with a bearish overall signal but bullish oscillators, while recent news highlights digital marketing initiatives and board appointments.
FIVE presents a compelling growth story with raised 2026 guidance and strong profitability metrics (ROE 28.25%), though premium valuation (P/E 18.81) and execution risks amid consumer spending pressures warrant caution. Upside potential exists if traffic and margin trends sustain, but investors should monitor inflation impacts on discretionary retail spending.
Merck (MRK) trades at $144.96, up 1.52% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 72.97% gross margin and 28.07% net income margin for 2025, though its P/E ratio of 113.9 indicates high valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid competitive pressures.
The outlook is mixed: analyst consensus is bullish with a $158.78 price target, but technical indicators and a high P/E suggest near-term caution. Key risks include integration challenges from acquisitions and macroeconomic headwinds affecting pharmaceutical R&D investment. Revenue growth and pipeline execution remain critical for sustained upside.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Five Below is a value-oriented retailer that operated 1,190 stores in the United States as of the end of fiscal 2021. Catering to teen and preteen consumers, stores feature a wide variety of merchandise, the vast majority of which is priced below $6. The assortment focuses on discretionary items in several categories, particularly leisure (such as sporting goods, toys, and electronics
Read more on FIVE →Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →